Clinical trial
Alemtuzumab in Treating Patients With Waldenstrom's Macroglobulinemia
NCT00081068 · Jonsson Comprehensive Cancer Center, Other · Withdrawn
Key facts
| NCT number | NCT00081068 |
|---|---|
| Title | Alemtuzumab in Treating Patients With Waldenstrom's Macroglobulinemia |
| Official title | Phase II Study of Campath-1H in Lymphoplasmacytic Lymphoma (Waldenstrom's Macroglobulinemia) |
| Lead sponsor | Jonsson Comprehensive Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Withdrawn |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Biological |
| Interventions | alemtuzumab |
| Enrollment | 0 |
| Start date | Jan 1, 2004 |
| First posted | Apr 8, 2004 |
| Last update posted | Jan 8, 2013 |
| Countries | Australia, Canada, France, United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: